Arcapta Inhaler Approved for COPD - Drugs.com MedNews
Links shared publicly online about this topic.
- 168total visits
Arcapta Inhaler Approved for COPD - Drugs.com MedNews
View full resource at drugs.com
Tags: COPD, Diet and Nutrition, Drug, FDA
Most Recently Shared on July 5, 2011 at 6:57 pm By:
Arcapta Inhaler Approved for COPD - http://bit.ly/jISZCv
Novartis launches Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary disease - MarketWatch
marketwatch.com — “Novartis launches Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary disease - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on March 19, 2012 at 9:20 pm By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Novartis launches Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary dis... http://t.co/TDxSDBVI
Arcapta Inhaler Approved for COPD --Doctors Lounge
doctorslounge.com — “Arcapta Inhaler Approved for COPD --Doctors Lounge” View full resource at doctorslounge.com
Most Recently Shared on July 5, 2011 at 4:31 pm By:
Arcapta Inhaler Approved for COPD: Helps prevent wheezing and shortness of breath http://bit.ly/kwkgAa
Arcapta Neohaler Approved for COPD - MPR
empr.com — “Novartis announced FDA approval of Arcapta Neohaler (indacaterol inhalation powder) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.” View full resource at empr.com
Most Recently Shared on July 5, 2011 at 3:50 pm By:
MPR News: Arcapta Neohaler Approved for COPD: Novartis announced FDA approval of Arcapta Neohaler (indacaterol i... http://bit.ly/jjGSF7
FDA Approves Arcapta Neohaler To Treat Chronic Obstructive Pulmonary Disease - QualityPoint Technologies
qualitypointtech.net — “The U.S. Food and Drug Administration approved Arcapta Neohaler (indacaterol inhalation powder) for the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough and excessive phlegm...” View full resource at qualitypointtech.net
Most Recently Shared on July 3, 2011 at 8:45 am By:
FDA Approves Arcapta Neohaler To Treat Chronic Obstructive Pulmonary Disease: The U.S. Food and Drug Administratio... http://bit.ly/iCpKuD
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms
rttnews.com — “Novartis AG (NVS), Friday announced that the US Food and Drug Administration has approved once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.” View full resource at rttnews.com
Most Recently Shared on July 2, 2011 at 2:30 am By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms, once a day bronchodilator - http://goo.gl/cd9hS
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease
drugs.com — “Arcapta Neohaler (indacaterol inhalation powder) is used to treat chronic obstructive pulmonary disease (COPD). Includes Arcapta Neohaler side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 2, 2011 at 12:11 am By:
Drugs and Devices OW OW Health
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease: The U.S. Food and Drug Admin... http://bit.ly/jIhfVN #drug
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease
drugs.com — “Arcapta Neohaler (indacaterol inhalation powder) is used to treat chronic obstructive pulmonary disease (COPD). Includes Arcapta Neohaler side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 1, 2011 at 11:39 pm By:
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease - http://bit.ly/mOT339
New Inhaler Drug for COPD Approved - QualityPoint Technologies
qualitypointtech.net — “WASHINGTON (MedPage Today) -- A new beta2-adrenergic agonist drug, indacaterol inhalation powder (Arcapta Neohaler), has won FDA approval as long-term maintenance therapy for chronic obstructive pulmonary disease, the agency announced.” View full resource at qualitypointtech.net
Most Recently Shared on July 1, 2011 at 11:00 pm By:
New Inhaler Drug for COPD Approved: WASHINGTON (MedPage Today) -- A new beta2-adrenergic agonist drug, indacaterol... http://bit.ly/iGWeAq
Medical News: New Inhaler Drug for COPD Approved - in Pulmonology, COPD from MedPage Today
medpagetoday.com — “WASHINGTON -- A new beta2-adrenergic agonist drug, indacaterol inhalation powder (Arcapta Neohaler), has won FDA approval as long-term maintenance therapy for chronic obstructive pulmonary disease, th” View full resource at medpagetoday.com
Most Recently Shared on July 1, 2011 at 10:13 pm By:
allergydropz Doctor, Surgeon, ENT Doctor, and Physician
Medpage Today: New Inhaler Drug for COPD Approved http://bit.ly/kTxsDs Full http://bit.ly/iZucPv
Medical News: New Inhaler Drug for COPD Approved - in Pulmonology, COPD from MedPage Today
medpagetoday.com — “WASHINGTON -- A new beta2-adrenergic agonist drug, indacaterol inhalation powder (Arcapta Neohaler), has won FDA approval as long-term maintenance therapy for chronic obstructive pulmonary disease, th” View full resource at medpagetoday.com
Most Recently Shared on July 1, 2011 at 10:11 pm By:
New Inhaler Drug for COPD Approved http://bit.ly/mdZsWr
FDA gives OK to Novartis' Arcapta - FiercePharma
fiercepharma.com — “The FDA has approved Novartis' once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with COPD. Read more...” View full resource at fiercepharma.com
Most Recently Shared on July 1, 2011 at 9:03 pm By:
FDA gives OK to Novartis' Arcapta. http://bit.ly/klzBJA
Novartis Faces Questions About Safety Of COPD Treatment | Markets | Minyanville.com
minyanville.com — “The company hopes to win approval for two dosing levels of inhaler for chronic disease. Safety concerns may trip up the panel of government advisers next week.” View full resource at minyanville.com
Most Recently Shared on March 5, 2011 at 6:28 am By:
Bart & Tara Health Organization
Novartis prepares for FDA meet on new #COPD medicine, Arcapta http://t.co/CM92ybG
Advertisement
